SEOUL, April 22 (Reuters) - Singapore's state investor Temasek will buy a 10 percent stake in South Korean biosimilar firm Celltrion for 207.9 billion won ($187.7 million), Celltrion said on Thursday.Celltrion, listed on the junior Kosdaq market, said the company would use the investment from Temesek to finance research and to expand its biosimilar business. Shares in the company, which focuses on monoclonal antibody capabilities, have risen a third so far this year. Full Story
